Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network
Saved in:
Wu, L.T., et al., Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction, vol. 116, n. 7, 2021, p. 1805-1816.
Ref.
574455
Location:
SIIS Archivo (R.696)
Palabras clave:
Drogodependencias, Drogas ilegales, Opiáceos, Tratamiento, Intervención, Médicos, Farmacia, Recetas médicas, Fármacos, Buprenorfina, Programas de mantenimiento, Colaboración, Atención comunitaria, Efectos, Actitudes usuarios, Actitudes personal, Satisfacción, Evaluación de servicios, EE.UU.
Drogodependencias, Drogas ilegales, Opiáceos, Tratamiento, Intervención, Médicos, Farmacia, Recetas médicas, Fármacos, Buprenorfina, Programas de mantenimiento, Colaboración, Atención comunitaria, Efectos, Actitudes usuarios, Actitudes personal, Satisfacción, Evaluación de servicios, EE.UU.
Similar Items: Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network
- Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial
- EXPANDING TREATMENT CAPACITY FOR OPIOID DEPENDENCE WITH OFFICE BASED TREATMENT WITH BUPRENORPHINE: NATIONAL SURVEYS OF PHYSICIANS
- Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
- INDICATIONS, REGLES ET TECHNIQUES DE PRESCRIPTION DE LA BUPRENORPHINE
- Determinants of buprenorphine treatment for opioid dependence
- WHICH INDICATORS CAN PUBLIC HEALTH AUTHORITIES USE TO MONITOR PRESCRIPTION DRUG ABUSE AND EVALUATE THE IMPACT OF REGULATORY MEASURES? CONTROLLING HIGH DOSAGE BUPRENORPHINE ABUSE